Table 4 |
||||||
|
Trial characteristics and quality assessment stratified by trial registration and overall risk of bias (N = 300) |
||||||
|
Trial Characteristics |
N |
Trial Registered |
Risk of Bias |
|||
|
|
||||||
|
300 |
Yes (N = 69;23%) |
No (N = 231;77%) |
Low (N = 23;8%) |
Unclear (N = 99;33%) |
High (N = 178;59%) |
|
|
|
||||||
|
Impact factor (median, range) |
294 |
4.017 (0.581-52.589) |
1.883 (0.080-15.484) |
2.948 (0.475-10.169) |
1.850 (0.329-52.589) |
2.342 (0.080-28.638) |
|
|
||||||
|
Continent of corresponding author |
||||||
|
Africa |
11 |
4 (5.8) |
7 (3.0) |
1 (4.4) |
4 (4.0) |
6 (3.4) |
|
Asia |
58 |
6 (8.7) |
52 (22.5) |
6 (26.1) |
27 (27.3) |
25 (14.0) |
|
Australia |
16 |
1 (1.5) |
15 (6.5) |
2 (8.7) |
7 (7.1) |
7 (3.9) |
|
Europe (excluding UK) |
91 |
17 (24.6) |
74 (32.0) |
6 (26.1) |
27 (27.3) |
58 (32.6) |
|
North America |
87 |
30 (43.5) |
57 (24.7) |
5 (21.7) |
19 (19.2) |
63 (35.4) |
|
South America |
7 |
2 (2.9) |
5 (2.2) |
- |
2 (2.0) |
5 (2.8) |
|
United Kingdom |
30 |
9 (13.0) |
21 (9.1) |
3 (13.0) |
13 (13.1) |
14 (7.9) |
|
|
||||||
|
Funding source specified |
194 |
62 (89.9) |
132 (57.1) |
23 (100.0) |
49 (49.5) |
122 (68.5) |
|
|
||||||
|
Industry supported |
67 |
24/62 (38.7) |
43/132 (32.6) |
7/23 (30.4) |
8/49 (16.3) |
52/122 (42.6) |
|
|
||||||
|
Primary outcome explicitly stated |
123 |
41 (59.4) |
82 (35.5) |
14 (60.9) |
34 (34.3) |
75 (42.1) |
|
|
||||||
|
Statistically significant outcome |
230 |
47 (68.1) |
183 (79.2) |
15 (65.2) |
83 (83.8) |
132 (74.2) |
|
|
||||||
|
Data Monitoring Committee |
14 |
9 (13.0) |
5 (2.2) |
1 (4.4) |
5 (5.1) |
8 (4.5) |
|
|
||||||
|
Jadad score (mean; median, range) |
300 |
2.99 (3; 0-5) |
2.44 (2; 0-5) |
3.96 (4; 3-5) |
2.24 (2; 1-5) |
2.56 (2; 0-5) |
|
|
||||||
|
Allocation Concealment |
||||||
|
Adequate |
65 |
24 (34.8) |
41 (17.8) |
20 (87.0) |
15 (15.2) |
30 (16.9) |
|
Unclear |
227 |
45 (65.2) |
182 (78.8) |
3 (13.0) |
84 (84.9) |
140 (78.7) |
|
Inadequate |
8 |
- |
8 (3.5) |
- |
- |
8 (4.5) |
|
|
||||||
|
Trial registered |
69 |
NA |
NA |
11 (47.8) |
10 (10.1) |
48 (27.0) |
|
|
||||||
|
Risk of Bias |
||||||
|
Low |
23 |
11 (15.9) |
12 (5.2) |
NA |
NA |
NA |
|
Unclear |
99 |
10 (14.5) |
89 (38.5) |
|||
|
High |
178 |
48 (69.6) |
130 (56.3) |
|||
|
|
||||||
|
Hamm et al. BMC Pediatrics 2010 10:96 doi:10.1186/1471-2431-10-96 |
||||||
